<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        13-211-98
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ACUITEL 20MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        QUINAPRIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Acuitel contains quinapril, which is one of a group of medicines called angiotensin converting enzyme (ACE) inhibitors.&nbsp; ACE inhibitors work by widening blood vessels in the body, which can reduce the pressure in the vessels.&nbsp;</p><p>Acuitel is used to treat high blood pressure, or to help treat heart failure.</p><p>You must talk to a doctor if you do not feel better or if you feel worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&Oslash;&nbsp; <strong>Do not take Acuitel</strong></p><p>&nbsp;</p><ul><li>if you are allergic to quinapril hydrochloride or any of the other ingredients of this medicine (listed in section 6).&nbsp; Signs of allergic reaction include itching, a rash on the skin or difficulty in breathing.&nbsp;</li></ul><p>&nbsp;</p><ul><li>if you are more than 3 months pregnant. (It is also better to avoid Acuitel in early pregnancy &ndash; see pregnancy section).</li></ul><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a condition called angioneurotic oedema (a swelling of the face, tongue or throat</p><p>which causes difficulty breathing).&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have aortic stenosis (narrowing of the main blood vessel from the heart).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney disease.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking sacubitril/valsartan, a medicine for heart failure.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&Oslash;&nbsp; <strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or pharmacist before taking Acuitel if:</p><p><strong>&nbsp;</strong></p><ul><li>you have kidney disease or use a haemodialysis machine (an artificial kidney).</li><li>If you experience jaundice or any other symptoms of liver disease, then contact your doctor immediately.</li><li>If you have heart disease or heart failure.</li><li>If you have previously had a sudden drop in blood pressure after taking medicines to treat high blood pressure<strong>.</strong></li><li>If you have collagen vascular disease (deposits of collagen in your blood vessels).</li><li>If you are having, or about to have, low density lipoprotein apheresis treatment (removal of cholesterol from your blood by machine).</li><li>If you suffer from allergies or asthma.</li><li>If you are having, or about to have, desensitisation treatment, i.e. to reduce the effects of an allergy to a bee or wasp sting.</li><li>If you have diabetes.</li><li>If you are also taking other medicines (see <strong>Other medicines and Acuitel</strong> section below)</li><li>If you are of child bearing potential (see pregnancy section).</li><li>If you are undergoing major surgery or being given anaesthesia in any treatment.</li><li>If you have intolerance to sugars such as lactose or galactose.</li><li>If you are taking any of the following medicines used to treat high blood pressure:</li></ul><p>- an angiotensin II receptor blocker (ARBs) (also known as sartans - for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems.</p><p>- aliskiren</p><ul><li>If you are simultaneously receiving an mTOR (mammalian target of Rapamycin) inhibitor (e.g. temsirolimus) or a DPP-4 (dipeptidyl-peptidase-4) inhibitor (e.g. vildagliptin) or a neutral endopeptidase inhibitor (e.g. racecadotril), as you may have an increased risk for angioedema (swelling of the face, eyes, tongue or throat). Special caution is advised if treatment with an mTOR inhibitor or DPP-4 inhibitor or a neutral endopeptidase inhibitor is initiated in patients who are already receiving an ACE inhibitor.</li><li>If you are taking medicines or have conditions which may decrease sodium levels in your blood.</li></ul><p>&nbsp;</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>&nbsp;</p><p>See also information under the heading Do not take Acuitel.</p><p>&nbsp;</p><p><strong>Other medicines and Acuitel</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. There are some medicines that may interact with Acuitel. Your doctor may need to change your dose and/or advise you to take other precautions if you are taking:</p><p>&nbsp;</p><ul><li>angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings &lsquo;Do not take Acuitel&rsquo; and &lsquo;Warnings and precautions&rsquo;).</li></ul><p>&nbsp;</p><ul><li>other blood pressure treatments and diuretics (including aliskiren and water tablets).</li></ul><p>&nbsp;</p><ul><li>medicines to treat infections called tetracyclines.</li></ul><p><strong>&nbsp;</strong></p><ul><li>antibiotics like sulfamethoxazole and trimethoprim.</li></ul><p><strong>&nbsp;</strong></p><ul><li>potassium supplements (this includes salt substitutes which often contain potassium).</li></ul><p><strong>&nbsp;</strong></p><ul><li>lithium (used to treat depression).</li></ul><p>&nbsp;</p><ul><li>non-steroidal anti-inflammatory pain killers (including aspirin or ibuprofen).</li></ul><p><strong>&nbsp;</strong></p><ul><li>steroids (including hydrocortisone, dexamethasone or prednisolone).</li></ul><p><strong>&nbsp;</strong></p><ul><li>procainamide (used to correct irregular heartbeats), cytostatic drugs (cancer therapy), immunosuppressants (for the treatment of autoimmune diseases e.g. Crohn&rsquo;s disease and rheumatoid arthritis) orallopurinol (for the treatment of chronic gout).</li></ul><p>&nbsp;</p><ul><li>indigestion and heartburn medicines (antacids).</li></ul><p>&nbsp;</p><ul><li>medicines that have a sedative effect.&nbsp; This includes alcoholic drinks and sleeping pills.</li></ul><p>&nbsp;</p><p>&nbsp;</p><ul><li>ACTH (tetracosactrin) (used to treat adrenal disorders).</li></ul><p><strong>&nbsp;</strong></p><ul><li>sympathomimetics (used to treat heart failure and shock).</li></ul><p><strong>&nbsp;</strong></p><ul><li>mTOR inhibitors used to treat kidney cancer (including temsirolimus) , certain antidiabetic drugs (DPP-4 inhibitors e.g. vildagliptin) or certain drugs against heart insufficiency and high blood pressure (neutral endopeptidase inhibitor, e.g. racecadotril): the risk of an angioedema (swelling of the face, eyes, tongue or throat) can be elevated.</li></ul><p><strong>&nbsp;</strong></p><ul><li>injectable gold treatments.</li></ul><p><strong>&nbsp;</strong></p><p><strong>Laboratory Tests</strong></p><p>&nbsp;</p><p>Acuitel may affect the results of some laboratory tests. Tell your doctor or hospital you are taking Acuitel if you need to have any tests carried out by your doctor or in hospital.</p><p>&nbsp;</p><p>&nbsp;</p><p>&Oslash;&nbsp; <strong>Acuitel with food and drink</strong></p><p>&nbsp;</p><p>&nbsp;Please see section 3 How to take Acuitel</p><p>&nbsp;</p><p>&Oslash;&nbsp; <strong>Pregnancy and breast-feeding</strong></p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy</strong></p><p>If you are pregnant think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will normally advise you to stop taking Acuitel before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Acuitel. Acuitel is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>If you are breast-feeding or&nbsp;about to start breast-feeding, ask your doctor or pharmacist for advice before taking this medicine. Breast-feeding new born babies (first few weeks after birth), and especially premature babies, is not recommended whilst taking Acuitel.</p><p>&nbsp;</p><p>In the case of an older baby your doctor should advise you on the benefits and risks of taking&nbsp;Acuitel whilst breast-feeding, compared&nbsp;with other treatments.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&Oslash;&nbsp; <strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Your tablets may affect your ability to drive or operate machines safely.&nbsp; They may make you feel dizzy or weary.&nbsp; If affected, do not drive or operate machinery and contact your doctor immediately.&nbsp;</p><p>&nbsp;</p><p><strong>Acuitel contains lactose</strong></p><p>&nbsp;</p><p>Acuitel contains lactose (a type of sugar). if you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Do not wait until your tablets are finished before seeing your doctor.</p><p>&nbsp;</p><p>The recommended dose of Acuitel is :</p><p><strong>&nbsp;</strong></p><p><strong>Adults</strong></p><p>&nbsp;</p><p>For treatment of hypertension (high blood pressure) the starting dose is usually 10 mg a day, which may be increased gradually up to a maximum of 80 mg a day.</p><p>&nbsp;</p><p>For the treatment of heart failure, if you are also taking water tablets (diuretics) to treat your high blood pressure, you are aged 65 or over, or you have kidney disease, the starting dose is usually 2.5 mg, which may be increased up to a maximum of 40 mg a day.</p><p>&nbsp;</p><p>Acuitel tablets should be taken either once or twice a day.&nbsp; Whatever dose you have been prescribed, follow your doctor&#39;s instructions exactly and never change the dose yourself.</p><p>&nbsp;</p><p>Swallow the tablets whole with water.&nbsp; <strong>Do not chew, divide</strong> or <strong>crush </strong>the tablets. The score line is only there to help you break the tablet if you have difficulty swallowing it whole .</p><p><strong>&nbsp;</strong></p><p><strong>Use in children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>Acuitel should not be used in children and adolescents under 18 years of age.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Acuitel than you should</strong></p><p>&nbsp;</p><p>Taking too many tablets at once may make you unwell.&nbsp; Tell your doctor or go to your nearest hospital casualty department immediately. Take along any tablets that are left, the packaging and the label so that the hospital staff can easily tell what medicine you have taken.</p><p>&nbsp;</p><p><strong>If you forget to take Acuitel</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you forget to take Acuitel</strong></p><p>&nbsp;</p><p>If you forget to take a dose, miss out the forgotten dose completely and take the next dose at the normal time.&nbsp; <strong>Do not take a double dose to make up for a foorgotten dose.</strong></p><p>&nbsp;</p><p><strong>If you stop taking Acuitel</strong></p><p>&nbsp;</p><p>Do not stop taking your tablets or alter the dose you are currently taking without seeing your doctor first. It is important to keep taking your tabletsas they help to control your blood pressure. Do not wait until your tablets are finished before seeing your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them.</p><p>&nbsp;</p><p><strong>STOP</strong> <strong>taking Acuitel and tell your doctor immediately </strong>if you experience any of the following symptoms after taking this medicine. These symptoms can be serious.</p><p>&nbsp;</p><ul><li>Severe allergic (anaphylactoid) reaction to this medicine. The symptoms include swelling of the face, tongue and throat which cause great difficulty breathing and angioedema (swelling of the deeper layer of the skin caused by a build-up of fluid).</li><li>Severe abdominal pain causing you to be sick, resulting from inflammation of the wall of the bowel (intestinal angioedema).</li><li>Severe abdominal pain that may spread to the back accompanied with feeling very unwell which may be a symptom of pancreatitis.</li><li>Chest pain, tightness of the chest, shortness of breath, wheezing or trouble breathing, which may be a symptom of angina or a heart attack and an irregular or rapid heartbeat (palpitations).</li><li>Weakness of arms, legs or face or problems speaking and visual disturbance which may be symptoms of a possible stroke.</li><li>Sudden severe headache, seizures, loss of coordination, loss of balance (cerebrovascular accident).</li><li>Skin rash, rawness, irritation, itching, hives, blistering, peeling and scaling.</li><li>Red or purple skin rash, skin pain, hives, blistering of the skin and mouth, nose ,eyes, genitals, facial and tongue swelling developing after a fever, flu like symptoms (Stevens Johnson Syndrome).</li></ul><ul><li>Feeling faint, particularly when suddenly standing up. This may mean your blood pressure is too low (hypotension). This is more likely to occur if you have been taking diuretics (water tablets), other blood pressure medication in addition to Acuitel, alcohol or if you are dehydrated or on dialysis.&nbsp;&nbsp; If you feel light headed or faint, lie down until this feeling passes.</li><li>Severe sore throat or severe mouth ulcers, particularly if you suffer from kidney problems or collagen vascular disease. This may mean you do not have enough of certain white blood cells (neutropenia/agranulocytosis), which may lead to increased risk of infection or fever.</li><li>Tightness of the chest, shortness of breath, wheezing or trouble breathing.</li><li>Yellowing of the skin or the whites of the eyes (jaundice).</li></ul><p>&nbsp;</p><p>The following side-effects have also been reported in patients with high blood pressure being treated with Acuitel::</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people:</strong></p><ul><li>increased potassium levels in the blood</li><li>sleeplessness</li><li>coughing; throat infection</li><li>nasal stuffiness and/or runny nose (rhinitis)</li><li>diarrhoea</li><li>indigestion</li><li>feeling or being sick</li><li>tiredness; weakness; lack of energy</li><li>headache</li><li>dizziness</li><li>sensation of tickling, pricking or burning on the skin</li><li>back pain</li><li>low blood pressure</li><li>pain in the muscle</li><li>increased creatinine and urea nitrogen in the blood</li></ul><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people:</strong></p><ul><li>depression; nervousness; confusion</li><li>widening of the blood vessels</li><li>fluid retention in the body</li><li>rapid heartbeat (tachycardia)</li><li>drowsiness</li><li>reduced vision (not correctable by glasses or contact lenses)</li><li>ringing or noises in the ears</li><li>spinning of the head or dizziness due to problems with the inner ear</li><li>dry mouth or throat</li><li>wind</li><li>excessive sweating</li><li>rash on the skin</li><li>failure/inability to achieve erection in males</li><li>protein in urine, urinary tract infection, reduced kidney function</li><li>inflammation of your sinuses (sinusitis), bronchitis, upper respiratory tract infection</li><li>fever</li></ul><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people:</strong></p><ul><li>taste disturbances</li><li>constipation</li><li>soreness of the tongue</li><li>disorders of balance</li><li>swelling of the lungs from an increase in eosinophils, a type of white blood cell (eosinophilic pneumonitis)</li></ul><p>&nbsp;</p><p><strong>Very rare: may affect up to 1 in 10,000 people:</strong></p><ul><li>blurring of vision</li><li>swelling of the walls of the bowels (intestines). Symptoms include abdominal pain, nausea, vomiting and intestinal cramps (intestinal angioedema)</li></ul><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong>:</p><ul><li>abnormal breakdown of red blood cells</li><li>bruising or a purple or red rash &ndash; purpura</li><li>abdominal pain caused by inflammation of the liver or blocked bile ducts</li><li>decreased numbers of white blood cells or decrease in blood platelets (thrombocytopenia) which may result in bruising or easy bleeding; low numbers of red blood cells (anaemia)</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased sodium concentrations in the blood</p><p>&nbsp;</p><ul><li>hair loss</li><li>sensitivity of the skin to light</li></ul><p>&nbsp;</p><p>Acuitel may cause certain changes in your blood and your doctor may do blood tests to monitor this. If you notice bruising, feeling very tired or if you are diabetic and notice sugar levels rising let your doctor know so blood tests can be arranged if necessary.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><ul><li>Saudi Arabia</li></ul><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:438px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>Call center : 19999</p><p>Fax: +966 11 205 7662</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website :https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.&nbsp;</p><p>&nbsp;</p><p>Do not use Acuitel after the expiry date which is stated on carton after EXP.&nbsp; The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Shlef life : 24 Months</p><p>&nbsp;</p><p>Store Below 25 &deg;C.&nbsp;</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste.&nbsp; Ask your pharmacist how to throw away medicines you no longer use.&nbsp; These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Acuitel tablets contain &nbsp;10 or 20 &nbsp;mg of the active ingredient quinapril.</p><p>&nbsp;</p><p>The other ingredients are<strong> </strong>&nbsp;magnesium carbonate, lactose, gelatin, crospovidone and magnesium stearate.</p><p>&nbsp;</p><p>The tablet coating contains candelilla wax and opadry White OY-S-7331</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Acuitel 10 mg Tables:

White, triangular, biconvex film-coated tablet with bisecting score on both side and debossing “10” on one side.

Acuitel 20 mg Tablets :

White, round, biconvex film-coated tablet with bisecting score on both side and debossing “20” on one side.


Each strength of Acuitel is supplied in blister pack of 30 tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong>&nbsp;&nbsp;</p><p>&nbsp;</p><p>Pfizer Pharma PFE GmbH</p><p>Linkster, Berlin</p><p>Germany&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer </strong>&nbsp;</p><p>&nbsp;</p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Betriebsst&auml;tte Freiburg</p><p>Mooswaldallee 1</p><p>79090 Freiburg</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2018 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">يحتوي هذا الدواء على كوينابرل ، الذي ينتمي لمجموعة من الأدوية تُسمى مثبطات الإنزيم المحول للأنجيوتنسين (ACE).&nbsp; تعمل مثبطات الإنزيم المحول للأنجيوتنسين من خلال توسيع الأوعية الدموية في الجسم، وهو ما من شأنه أن يخفض الضغط داخل الأوعية.&nbsp;</p><p style="direction: rtl;">يتم استخدام هذه المثبطات لعلاج ضغط الدم المرتفع، أو للمساعدة في علاج فشل القلب.</p><p style="direction: rtl;">يجب أن تتحدث إلى أحد الأطباء إذا لم تشعر بتحسن أو إذا ساءت حالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال أكويتل</strong></p><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">إذا كنت تعاني من الحساسية تجاه هيدروكلوريد كوينابرل &nbsp;أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).&nbsp; تتضمن علامات تفاعل الحساسية الحكة أو طفح على الجلد أو صعوبة في التنفس.&nbsp;</li></ul><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">إذا كنت حاملًا ومضى من حملك ما يزيد عن 3 أشهر. (من الأفضل كذلك تجنب تناول أكويتل خلال الفترة الأولى من الحمل &ndash; انظر قسم الحمل).</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حالة تسمى وذمة وعائية عصبية (تورم في الوجه أو اللسان أو الحلق</p><p style="direction: rtl;">مما يسبب صعوبة في التنفس).&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تضيق الأبهر (ضيق وعاء الدم الرئيسي الناقل للدم من القلب).</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض بالكلى.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض السكري أو خلل في وظائف الكلى وتتلقى العلاج بدواء خافض لضغط الدم يحتوي على أليسكيرين.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول ساكوبتريل/فالسارتان، وهو دواء لفشل القلب.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال أكويتل</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">تحدث إلى طبيبك أو الصيدلي قبل تناول أكويتل إذا:</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">تعاني من مرض بالكلي أو تستخدم جهاز ديلزة دموية (كلية صناعية).</li><li style="direction: rtl;">مصابًا باليرقان أو أي أعراض أخرى لمرض بالكبد، فاتصل حينها بطبيبك على الفور.</li><li style="direction: rtl;">تعاني من مرض بالقلب أو فشل القلب.</li><li style="direction: rtl;">عانيت في السابق من انخفاض مفاجئ في ضغط الدم بعد تناول أدوية لعلاج ضغط الدم المرتفع<strong>.</strong></li><li style="direction: rtl;">تعاني من مرض وعائي كولاجيني (وجود رواسب من الكولاجين في أوعيتك الدموية).</li><li style="direction: rtl;">تخضع للعلاج بفِصادة البروتين الشحمي منخفض الكثافة (إزالة الكولستيرول من دمك بواسطة جهاز) أو كنت على وشك الخضوع له.</li><li style="direction: rtl;">تعاني من الحساسية أو الربو.</li><li style="direction: rtl;">تتلقى علاجًا لإزالة الحساسية، أي علاج لتقليل آثار الحساسية للدغة النحل أو الزنبور، أو على وشك تلقيه.</li><li style="direction: rtl;">تعاني من مرض السكري.</li><li style="direction: rtl;">تتناول أدوية أخرى في الوقت نفسه.</li><li style="direction: rtl;">سيدة قادرة على الإنجاب (انظري قسم الحمل).</li><li style="direction: rtl;">ستخضع لجراحة كبرى أو يتم إعطاؤك مخدرًا في أي علاج.</li><li style="direction: rtl;">تعاني من عدم تحمل السكريات مثل اللاكتوز أو الجالاكتوز.</li><li style="direction: rtl;">تتناول أي من الأدوية التالية المستخدمة لعلاج ضغط الدم المرتفع:</li></ul><p style="direction: rtl;">- حاصرات مستقبلات الأنجيوتنسين الثاني (ARBs) (تعرف كذلك باسم فئة السارتان - على سبيل المثال فالسارتان، تيلميسارتان، إيربيسارتان)، خاصة إذا كنت تعاني من مشكلات بالكلى مرتبطة بمرض السكري.</p><p style="direction: rtl;">- أليسكيرين</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتلقى بشكل متزامن مثبط mTOR (البروتين المستهدَف براباميسين لدى الثدييات) (مثل تمسيروليموس) أو مثبط DPP-4 (ثنائي بيبتيديل &ndash;بيبتيداز-4) مثل (فيلداجليبتين) أو مثبط إنزيم إندوبيبتيداز المحايد (مثل راسيكادوتريل)، فقد يرتفع خطر الإصابة بالتورم الوعائي (تورم الوجه، أو العينين، أو اللسان، أو الحلق). يُنصح بتوخي الحذر الخاص إذا تم بدء علاج باستخدام مثبط البروتين المستهدَف براباميسين لدى الثدييات أو مثبط ثنائي بيبتيديل &ndash;بيبتيداز-4 أو مثبط إنزيم إندوبيبتيداز المحايد في المرضى الذين يتلقون أحد مثبطات الإنزيم المحول للأنجيوتنسين بالفعل.</p><p style="direction: rtl;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أدوية أو مصابًا بحالات قد تقلل من مستويات الصوديوم في دمك.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">من الممكن أن يقوم طبيبك بفحص وظائف الكلى وضغط الدم لديك ونسبة الإلكتروليتات (مثل البوتاسيوم) في دمك على فترات منتظمة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">انظر أيضًا المعلومات الموجودة أسفل العنوان &quot;لا تتناول أكويتل في الحالات التالية&quot;.</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">أخبِر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، بما فيها تلك التي يتم الحصول عليها دون وصفة طبية. توجد بعض الأدوية التي يمكن أن تتفاعل مع أكويتل. قد يحتاج طبيبك إلى تغيير جرعتك و/أو اتخاذ احتياطات أخرى:</p><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">حاصرات مستقبلات الأنجيوتنسين الثاني (ARB) أو أليسكيرين (انظر أيضًا المعلومات الموجودة أسفل العنوانين &quot;لا تتناول أكويتل في الحالات التالية&quot; و&quot;تحذيرات واحتياطات&quot;).</li></ul><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">علاجات ضغط الدم الأخرى ومدرات البول (بما في ذلك أليسكيرين وأقراص الماء).</li></ul><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">أدوية علاج حالات العدوى، التي يطلق عليها تتراسيكلينات.</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">المضادات الحيوية مثل سلفاميثوكسازول وتريميثوبريم.</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">مكملات البوتاسيوم (تتضمن هذه بدائل الملح التي تحتوي غالبًا على البوتاسيوم).</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">الليثيوم (يستخدم لعلاج الاكتئاب).</li></ul><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">مسكنات الألم غير الستيرويدية المضادة للالتهاب (بما في ذلك أسبرين أو إيبوبروفين).</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">الستيرويدات (بما في ذلك هيدروكورتيزون أو ديكساميثازون أوبريدنيزولون).</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">بروكايناميد (يستخدم لتصحيح ضربات القلب غير المنتظمة)، والعقاقير الكابتة لنمو الخلايا (علاج السرطان)، والأدوية الكابتة للمناعة (لعلاج أمراض المناعة الذاتية مثل مرض كرون والتهاب المفاصل الروماتويدي)، وألوبورينول (لعلاج النقرس المزمن).</li></ul><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">أدوية عسر الهضم وحرقة فم المعدة (مضادات الحموضة).</li></ul><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">الأدوية التي لها تأثير مهدئ،&nbsp; ويتضمن هذا المشروبات الكحولية والحبوب المنومة.</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">الهرمون الموجه لقشر الكظر (ACTH) (تتراكوساكترين) (يستخدم لعلاج الاضطرابات الكظرية).</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">الأدوية المحاكية للتأثير العصبي الودي (تستخدم لعلاج فشل القلب والصدمة).</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">مثبطات البروتين المستهدَف براباميسين لدى الثدييات (mTOR) المستخدمة لعلاج سرطان الكلى (بما في ذلك تمسيروليموس)، أو بعض الأدوية المضادة لمرض السكري (مثبطات ثنائي بيبتيديل &ndash;بيبتيداز-4 مثل فيلداجليبتين)، أو بعض العقاقير المستخدمة لعلاج قصور القلب وضغط الدم المرتفع (مثبط إنزيم إندوبيبتيداز المحايد مثل راسيكادوتريل): قد يرتفع خطر الإصابة بتورم وعائي (تورم الوجه، أو العينين، أو اللسان، أو الحلق).</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><ul><li style="direction: rtl;">علاجات الذهب القابلة للحقن.</li></ul><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">الاختبارات المعملية</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قد يؤثر أكويتل على نتائج بعض الاختبارات المعملية. أخبر طبيبك أو المستشفى بأنك تتناول أكويتل إذا كنت تحتاج إلى إجراء أي اختبارات بواسطة طبيبك أو المستشفى.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تناول أكويتل مع الطعام والشراب</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يمكن تناول أكويتل مع الطعام أو دونه.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرضاعة</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">الحمل</p><p style="direction: rtl;">إذا كنتِ حاملًا أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين لإنجاب طفل، فاستشيري طبيبك أو الصيدلي قبل تناول هذا الدواء. سوف ينصحكِ طبيبكِ عادة بالتوقف عن تناول أكويتل قبل أن تصبحي حاملًا أو بمجرد علمكِ بأنكِ حامل وسينصحكِ بتناول دواء آخر بدلًا من أكويتل. لا يوصى بتناول أكويتل خلال الفترة الأولى من الحمل، ويجب عدم تناوله بعد مضي ما يزيد عن 3 أشهر من الحمل، حيث قد يسبب لطفلكِ ضررًا خطيرًا إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">الرضاعة الطبيعية</p><p style="direction: rtl;">إذا كنتِ تُرضعين رضاعة طبيعية أو على وشك أن تبدئي في الرضاعة الطبيعية، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء. لا ينصح بإرضاع الأطفال حديثي الولادة رضاعة طبيعية (في الأسابيع الأولي القليلة بعد الولادة)، وخصوصًا الأطفال المبتسرين، أثناء تناول أكويتل<strong>.</strong></p><p style="direction: rtl;">وفي حالة إرضاع طفل أكبر عمرًا، ينبغي أن ينصحكِ طبيبكِ بشأن فوائد تناول أكويتل ومخاطره أثناء الرضاعة الطبيعية مقارنةً بغيره من العلاجات.</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تأثير أكويتل على القيادة واستخدام الآلات</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قد تؤثر الأقراص التي تتناولها على قدرتك على القيادة أو تشغيل الآلات بأمان.&nbsp; وقد تجعلك تشعر بالدوار أو الإنهاك.&nbsp; إذا أصبت بذلك، فلا تقم بالقيادة أو تشغيل الآلات وتواصل مع طبيبك على الفور.&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يحتوي أكويتل على اللاكتوز</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">اللاكتوز هو أحد أنواع السكريات، وإذا أخبرك طبيبك أنك مصاب بعدم تحمل لبعض السكريات، فتواصل معه قبل تناول هذا المنتج الدوائي.</p><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">احرص دومًا على تناول هذا الدواء بالضبط كما أخبرك طبيبك أو الصيدلي. راجع طبيبك أو الصيدلي إذا لم تكن واثقًا مما عليك فعله.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لا تنتظر حتى تنتهي أقراصك قبل زيارة طبيبك.</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><strong>البالغون</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>لعلاج</strong> <strong>ارتفاع</strong> <strong>ضغط</strong> <strong>الدم</strong> (<strong>ضغط</strong> <strong>الدم</strong> <strong>المرتفع</strong>) <strong>تكون</strong> <strong>جرعة</strong> <strong>البدء</strong> <strong>عادةً</strong> 10 <strong>ملجم</strong> <strong>في</strong> <strong>اليوم</strong><strong>،</strong> <strong>ويمكن</strong> <strong>زيادتها</strong> <strong>تدريجيًا</strong> <strong>حتى</strong> <strong>تصل</strong> <strong>إلى</strong> 80 <strong>ملجم</strong> <strong>في</strong> <strong>اليوم</strong> <strong>كحد</strong> <strong>أقصى</strong>.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>لعلاج</strong> <strong>فشل</strong> <strong>القلب،</strong> <strong>إذا</strong> <strong>كنت</strong> <strong>تستخدم</strong> <strong>أقراص</strong> <strong>الماء</strong> (<strong>مدرات</strong> <strong>البول</strong>) <strong>لعلاج</strong> <strong>ضغط</strong> <strong>الدم</strong> <strong>المرتفع،</strong> <strong>وتبلغ</strong> <strong>من</strong> <strong>العمر</strong> 65 <strong>عامًا</strong> <strong>أو</strong> <strong>أكثر،</strong> <strong>أو</strong> <strong>كان</strong> <strong>لديك</strong> <strong>مرض</strong> <strong>بالكلى،</strong> <strong>تكون</strong> <strong>جرعة</strong> <strong>البدء</strong> <strong>عادةً</strong> 2.5 <strong>ملجم،</strong> <strong>ويمكن</strong> <strong>زيادتها</strong> <strong>حتى</strong> <strong>تصل</strong> <strong>إلى</strong> 40 <strong>ملجم</strong> <strong>في</strong> <strong>اليوم</strong> <strong>كحد</strong> <strong>أقصى</strong>.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">ينبغي تناول أقراص أكويتل إما مرة واحدة أو مرتين في اليوم.&nbsp; اتبع تعليمات طبيبك بالضبط ولا تغير الجرعة أبدًا من تلقاء نفسك، أيًا ما كانت الجرعة الموصوفة لك.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قم بابتلاع الأقراص كاملةً مع الماء.&nbsp; <strong>لا تمضغ</strong> الأقراص <strong>ولا تقسمها ولا تطحنها</strong>.</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><strong>الاستخدام مع الأطفال والمراهقين</strong></p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;">ينبغي ألا يستخدم أكويتل مع الأطفال والمراهقين البالغين من العمر أقل من 18 عامًا.</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><strong>الجرعة الزائدة من أكويتل</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">تناول الأقراص بكمية مفرطة في آن واحد يمكن أن يسبب لك التوعك.&nbsp; إذا حدث ذلك، فأخبر طبيبك أو اذهب إلى قسم الحوادث في أقرب مستشفى على الفور.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>نسيان تناول جرعة أكويتل</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لا تقلق.&nbsp; إذا نسيت تناول إحدى الجرعات، فتخط الجرعة التي نسيتها تمامًا، وتناول الجرعة التالية في موعدها الطبيعي.&nbsp; لا تتناول جرعة مضاعفة لتعويض جرعة فائتة.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>التوقف عن تناول أكويتل</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لا تتوقف عن تناول أقراصك ولا تقم بتغيير الجرعة التي تتناولها حاليًا دون الرجوع لطبيبك أولًا. من المهم أن تواصل تناول أقراصك، فهي تساعدك على التحكم في ضغط دمك.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">إذا كان لديك المزيد من الأسئلة بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">كما هو الحال بالنسبة لجميع الأدوية، من الممكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">توقف عن تناول أكويتل وأخبر طبيبك على الفور إذا أصبت بأي من الأعراض التالية بعد تناول هذا الدواء. يمكن لهذه الأعراض أن تكون خطيرة.</p><p style="direction: rtl;">&nbsp;</p><ul><li style="direction: rtl;">تفاعل حساسية شديد الحدة (تفاعل تأقي) تجاه هذا الدواء. تتضمن الأعراض تورم الوجه واللسان والحلق مما يسبب صعوبة كبيرة في التنفس والوذمة الوعائية (تورم الطبقة الأعمق من الجلد بسبب تراكم السوائل).</li><li style="direction: rtl;">ألم شديد في البطن يسبب لك التقيؤ وهو ناتج عن التهاب جدار الأمعاء (الوذمة الوعائية المعوية).</li><li style="direction: rtl;">ألم شديد في البطن يمكن أن ينتشر إلى الظهر ويصحبه شعور بالتوعك الشديد وقد يكون عَرَضًا لالتهاب البنكرياس.</li><li style="direction: rtl;">ألم في الصدر أو ضيق الصدر أو ضيق التنفس أو الأزيز أو صعوبة التنفس، ما قد يكون عرضًا للذبحة الصدرية أو لحدوث أزمة قلبية وعدم انتظام ضربات القلب أو زيادة سرعتها (الخفقان).</li><li style="direction: rtl;">ضعف في الذراعين أو الساقين أو الوجه أو صعوبة في التحدث واعتلال بصري، التي قد تكون أعراضًا لسكتة دماغية محتملة.</li><li style="direction: rtl;">صداع شديد ومفاجئ، وحدوث نوبات، وفقد التناسق العضلي، وفقد التوازن (حادث دماغي وعائي).</li><li style="direction: rtl;"><strong>طفح،</strong> <strong>وتقحف</strong> (<strong>تقشف</strong>)<strong>،</strong> <strong>وتهيج،</strong> <strong>وحكة،</strong> <strong>وتبثر،</strong> <strong>وتقشر</strong> <strong>وتكون</strong> <strong>قشور</strong> <strong>سميكة</strong> <strong>بالجلد</strong>.</li><li style="direction: rtl;"><strong>الطفح</strong> <strong>الجلدي</strong> <strong>الأحمر</strong> <strong>أو</strong> <strong>الأرجواني</strong> <strong>وألم</strong> <strong>الجلد</strong> <strong>وتبثر</strong> <strong>بالجلد</strong> <strong>والفم</strong> <strong>والأنف</strong> <strong>والعينين</strong> <strong>والمناطق</strong> <strong>التناسلية</strong> <strong>وتورم</strong> <strong>الوجه</strong> <strong>واللسان</strong> <strong>الذي</strong> <strong>يظهر</strong> <strong>بعد</strong> <strong>الإصابة</strong> <strong>بحمى،</strong> <strong>وأعراض</strong> <strong>تشبه</strong> <strong>الإنفلونزا</strong> (<strong>متلازمة</strong> <strong>ستيفنز</strong> <strong>جونسون</strong>).</li></ul><ul><li style="direction: rtl;">الشعور بالضعف، خصوصًا عند الوقوف فجأةً. قد يعني هذا أن ضغط دمك منخفض جدًا (انخفاض ضغط الدم). تزداد احتمالية حدوث هذا في حالة استعمالك لمدرات البول (أقراص الماء) أو لدواء آخر لضغط الدم بالإضافة إلى أكويتل، أو عند تناولك للكحوليات أو إذا كنت تعاني من الجفاف أو كنت تخضع للديلزة.&nbsp;&nbsp; إذا كنت تشعر بدوار خفيف أو بالضعف، فاستلقِ حتى يزول هذا الشعور.</li><li style="direction: rtl;">احتقان الحلق الشديد أو قرح الفم الشديدة خصوصًا إذا كنت تعاني من مشكلات في الكلى أو مرض وعائي كولاجيني. قد يعني هذا أنه ليس لديك ما يكفي من بعض خلايا الدم البيضاء المعينة (قلة العدلات/ندرة المحببات) مما قد يؤدي إلى زيادة خطر الإصابة بالعدوى أو الحمى.</li><li style="direction: rtl;">ضيق الصدر، أو ضيق التنفس، أو الأزيز، أو صعوبة التنفس.</li><li style="direction: rtl;">اصفرار الجلد أو بياض العينين (اليرقان).</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">تم الإبلاغ أيضًا عن الآثار الجانبية التالية في المرضى الذين يعانون من ضغط دم مرتفع ويتلقون العلاج بأكويتل. إذا تفاقمت شدة أي من هذه الآثار الجانبية أو إذا لاحظت ظهور آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار طبيبك:</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">شائعة: قد تصيب ما يصل إلى شخص واحد من كل 10 أشخاص:</p><ul><li style="direction: rtl;">ارتفاع مستويات البوتاسيوم في الدم</li><li style="direction: rtl;">الأرق</li><li style="direction: rtl;">السعال؛ عدوى بالحلق</li><li style="direction: rtl;">انسداد الأنف و/أو سيلان الأنف (التهاب الغشاء المخاطي الأنفي)</li><li style="direction: rtl;">الإسهال</li><li style="direction: rtl;">عسر الهضم</li><li style="direction: rtl;">الشعور بالغثيان أو التقيؤ</li><li style="direction: rtl;">التعب؛ الضعف؛ فقدان الطاقة</li><li style="direction: rtl;">الصداع</li><li style="direction: rtl;">الدوار</li><li style="direction: rtl;">الشعور بوخز أو نخز أو حرقان في الجلد</li><li style="direction: rtl;">ألم بالظهر</li><li style="direction: rtl;">ضغط الدم المنخفض</li><li style="direction: rtl;">ألم في العضلات</li><li style="direction: rtl;">ارتفاع تركيزات الكرياتينين ونيتروجين اليوريا في الدم</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل 100 شخص:</p><ul><li style="direction: rtl;">الاكتئاب؛ العصبية؛ التشوش</li><li style="direction: rtl;">توسع الأوعية الدموية</li><li style="direction: rtl;">احتباس السوائل في الجسم</li><li style="direction: rtl;">سرعة ضربات القلب (تسرع القلب)</li><li style="direction: rtl;">النعاس</li><li style="direction: rtl;">انخفاض القدرة على الإبصار (غير قابل للتصحيح بواسطة النظارات الطبية أو العدسات اللاصقة)</li><li style="direction: rtl;">طنين أو ضجيج في الأذنين</li><li style="direction: rtl;">الدوخة أو الدوار نتيجة لمشكلات في الأذن الداخلية</li><li style="direction: rtl;">جفاف الفم أو الحلق</li><li style="direction: rtl;">الريح</li><li style="direction: rtl;">العرق المفرط</li><li style="direction: rtl;">طفح على الجلد</li><li style="direction: rtl;">الفشل/عدم القدرة على تحقيق الانتصاب في الذكور</li><li style="direction: rtl;">وجود بروتين في البول، عدوى المسالك البولية، انخفاض في وظائف الكلى</li><li style="direction: rtl;">التهاب جيوبك، الالتهاب الشعبي، عدوى الجزء العلوي من الجهاز التنفسي</li><li style="direction: rtl;">الحمى</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">نادرة: قد تصيب ما يصل إلى شخص واحد من بين كل 1000 شخص:</p><ul><li style="direction: rtl;">اضطرابات التذوق</li><li style="direction: rtl;">الإمساك</li><li style="direction: rtl;">تقرح اللسان</li><li style="direction: rtl;">اضطرابات التوازن</li><li style="direction: rtl;">تورم الرئتين بسبب زيادة في اليوزينيات، وهي نوع من خلايا الدم البيضاء (الالتهاب الرئوي اليوزيني)</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">نادرة جدًا: قد تصيب ما يصل إلى شخص واحد من بين كل 10000 شخص:</p><ul><li style="direction: rtl;">تغيُّم الرؤية</li><li style="direction: rtl;">تورم الجدران المعوية (جدران الأمعاء). تتضمن الأعراض ألم البطن والغثيان والقيء وتقلصات الأمعاء (الوذمة الوعائية المعوية)</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتاحة:</p><ul><li style="direction: rtl;">تحلل غير طبيعي لخلايا الدم الحمراء</li><li style="direction: rtl;">التكدم أو الطفح الجلدي الأرجواني أو الأحمر - الفرفرية</li><li style="direction: rtl;">ألم البطن الناتج بسبب التهاب الكبد أو انسداد قنوات الصفراء</li><li style="direction: rtl;">انخفاض عدد خلايا الدم البيضاء أو انخفاض عدد الصفيحات الدموية (قلة الصفيحات) مما قد يؤدي إلى التكدم أو سهولة حدوث النزيف؛ قلة عدد خلايا الدم الحمراء (فقر الدم)</li><li style="direction: rtl;">انخفاض تركيزات الصوديوم في الدم</li><li style="direction: rtl;">تساقط الشعر</li><li style="direction: rtl;">حساسية الجلد تجاه الضوء</li></ul><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">قد يسبب أكويتل تغيرات معينة في دمك وقد يُخضعك طبيبك لفحوصات دم لمراقبة ذلك. إذا لاحظت وجود تكدم أو شعورًا بالتعب أو إذا كنت مصابًا بداء السكري ولاحظت أن مستويات السكر ترتفع فأخبر طبيبك حتى يمكن الترتيب لإجراء فحوصات الدم إذا لزم الأمر.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>&nbsp;</strong></p><p style="direction: rtl;"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p style="direction: rtl;">إذا أُصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">للإبلاغ عن الأعراض الجانبية</p><p style="direction: rtl;"><em>&nbsp;</em></p><ul><li style="direction: rtl;">المملكة العربية السعودية</li></ul><p style="direction: rtl;"><em>&nbsp;</em></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="direction:rtl"><tbody><tr><td style="vertical-align:top"><p>المركز الوطني للتيقظ والسلامة الدوائية</p><ul><li>فاكس: 00966112057662</li><li>رقم الهاتف: 0096612038222 تحويلة 2317-2356-2340</li><li>الرقم المجاني: 19999</li><li>البريد الإلكتروني: <em>npc.drug@sfda.gov.sa</em></li><li>الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul><p>&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لا تستخدم أكويتل بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية بعد رمز &quot;EXP&quot;.&nbsp; يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">تاريخ الصلاحية : 24 شهر .</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يخزن الدواء في درجة حرارة أقل من 30 درجة مئوية.&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية.&nbsp; اسأل الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد تستخدمها.&nbsp; ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">تحتوي<strong> </strong>أقراص<strong> </strong>أكويتل<strong> </strong>على<strong> </strong>10<strong> </strong>أو<strong> </strong>20<strong> </strong>ملجم<strong> </strong>من<strong> </strong>المكون<strong> </strong>الفعال<strong> </strong>كوينابرل <strong>.</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">المكونات الأخرى هي كربونات المغنيسيوم، ولاكتوز، وجيلاتين، وكروسبوفيدون وستيارات المغنيسيوم.</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">يحتوي غلاف القرص على شمع الفربيون وغلاف أوبادراي أبيض OY-S-7331</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            اكويتل 10: قرص أبيض مثلث الشكل مغلف بطبقة رقيقة ومحدب الجانبين مع حز نصفي على كلا الجانبين ونقش "10" على أحد الجانبين.
اكويتل  20: قرص أبيض مستدير الشكل مغلف بطبقة رقيقة ومحدب الجانبين مع حز نصفي على كلا الجانبين ونقش "20" على أحد الجانبين.


يتوفر كل تركيز لأكويتل في عبوة بها شرائط دواء تحتوي على 30 قرصًا.  

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>مالك رخصة التسويق</strong></p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">Pfizer Pharma PFE GmbH, Linkster, Berlin, Germany</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;"><strong>الجهة المصنعة </strong>&nbsp;</p><p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">Pfizer Manufacturing Deutschland GmbH</p><p style="direction: rtl;">Betriebsst&auml;tte Freiburg</p><p style="direction: rtl;">Mooswaldallee 1</p><p style="direction: rtl;">79090 Freiburg</p><p style="direction: rtl;">Germany، ألمانيا</p><p style="direction: rtl;">&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس/آب 2017 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acuitel Tablets 10 mg
Acuitel Tablets 20 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 10 mg tablet contains: quinapril hydrochloride 10.832 mg (equivalent to 10 mg quinapril base)
Each 20 mg tablet contains: quinapril hydrochloride 21.664 mg (equivalent to 20 mg quinapril base)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acuitel 10 mg:

White, triangular, biconvex film-coated tablet with bisecting score on both side and debossing “10” on one side.

Acuitel 20 mg:

White, round, biconvex film-coated tablet with bisecting score on both side and debossing “10” on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>(1) For the treatment of all grades of essential hypertension. Acuitel is effective as monotherapy or concomitantly with diuretics in patients with hypertension (see sections 4.3, 4.4, 4.5 and 5.1).</p><p>&nbsp;</p><p>&nbsp;</p><p>(2) For the treatment of congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside. Treatment of congestive heart failure with Acuitel should always be initiated under close medical supervision.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p><strong>Adults</strong></p><p><strong>&nbsp;</strong></p><p><strong>Hypertension</strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp; Monotherapy:</p><p>The recommended initial dosage is 10 mg once daily in uncomplicated hypertension. Depending upon clinical response, patient&#39;s dosage may be titrated (by doubling the dose allowing adequate time for dosage adjustment) to a maintenance dosage of 20 mg/day to 40 mg/day given as a single dose or divided into 2 doses. Long-term control is maintained in most patients with a single daily dosage regimen. Patients have been treated with dosages up to 80 mg/day. Take either with or without food. The dose should always be taken at about the same time of day to help increase compliance.</p><p>&nbsp;</p><p>-&nbsp; Concomitant Diuretics:</p><p>In order to determine if excess hypotension will occur, an initial dosage of 2.5 mg of Acuitel is recommended in patients who are being treated with a diuretic. After this the dosage of Acuitel should be titrated (as described above) to the optimal response (see sections 4.3, 4.4, 4.5 and 5.1).</p><p>&nbsp;</p><p><strong>Congestive Heart Failure</strong></p><p><strong>&nbsp;</strong></p><p>In order to closely monitor patients for symptomatic hypotension, a single 2.5 mg initial dosage is recommended. After this, patients should be titrated to an effective dose: (up to 40 mg/day) given in 1 or 2 doses with concomitant diuretic and/or cardiac glycoside therapy. Patients are usually maintained effectively on doses of 10 mg/day to 20 mg/day given with concomitant therapy. Take either with or without food. The dose should always be taken at about the same time of day to help increase compliance.</p><p>&nbsp;</p><p>&nbsp;In the treatment of severe or unstable congestive heart failure, Acuitel should always be initiated in hospital under close medical supervision.</p><p>&nbsp;</p><p>Other patients who may also be considered to be at higher risk and should have treatment initiated in hospital include: patients who are on high dose loop diuretics (e.g. &gt; 80 mg furosemide) or on multiple diuretic therapy, have hypovolemia, hyponatremia (serum sodium &lt; 130 mgEq/l) or systolic blood pressure &lt; 90 mm Hg, are on high dose vasodilator therapy, have a serum creatinine &gt; 150 &micro;mol/l or are aged 70 years or over.</p><p>&nbsp;</p><p><u>Elderly/Renal Impairment</u></p><p><strong>&nbsp;</strong></p><p>In elderly patients and in patients with a creatinine clearance of less than 40 mL/min, an initial dosage in essential hypertension of 2.5 mg is recommended followed by titration to the optimal response (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Currently available data are described in sections 5.1 and 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p>Methode of administration</p><p>&nbsp;</p><p>For Oral use . The tablets should not be chewed, crushed or divided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acuitel is contraindicated :

•	In patients with hypersensitivity to the active substance or any of the excipients listed in section 6.1.

•	In the second and third trimesters of pregnancy (see sections 4.4 and 4.6).

•	In patients with a history of angioedema related to previous treatment with angiotensin converting enzyme (ACE) inhibitors.

•	In patients with hereditary/idiopathic angioneurotic oedema.

•	In patients with dynamic left ventricular outflow obstruction.

•	With adminstrationof Acuitel with aliskiren-containing products  in patients with diabetes mellitus or in patients with renal impairment (glomerular filtration [GFR] < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).

•	in combination with sacubitril/valsartan due to the increased risk of angioedema. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Aortic Stenosis</em></p><p>&nbsp;</p><p>Quinapril should be used in caution in selected patients with aortic stenosis.</p><p>&nbsp;</p><p><u>Sensitivity Reactions:</u></p><p>Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma, e.g., purpura, photosensitivity, urticaria, necrotising angiitis, respiratory distress including pneumonitis and pulmonary oedema, and anaphylactic reactions.</p><p>&nbsp;</p><p>Patients haemodialysed using high-flux polyacrylonitrile (&#39;AN69&#39;) membranes are highly likely to experience anaphylactoid reactions if they are treated with ACE inhibitors. This combination should therefore be avoided, either by use of alternative antihypertensive drugs or alternative membranes for haemodialysis. Similar reactions have been observed during low density lipoprotein (LDL) apheresis with dextran-sulfate. This method should therefore not be used in patients treated with ACE inhibitors.</p><p>&nbsp;</p><p><u>Impaired Hepatic Function</u><u>: </u></p><p>Quinapril when combined with a diuretic should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. The metabolism of quinapril to quinaprilat is normally dependent upon hepatic esterase. Quinaprilat concentrations are reduced in patients with alcoholic cirrhosis due to impaired deesterification esterification of quinapril.</p><p>&nbsp;</p><p>Rarely, ACE inhibitors have been associated with a syndrome beginning as a cholestatic jaundice and</p><p>progressing to a fulminant hepatic necrosis (in some cases fatal). Patients who during ACE inhibitor</p><p>therapy, experience jaundice or clearly elevated hepatic enzymes should discontinue quinapril and</p><p>receive appropriate medical follow-up.</p><p>&nbsp;</p><p><u>Cough</u>:</p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p>&nbsp;</p><p><u>Surgery/Anaesthesia</u>:</p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, quinapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion (see section 4.5).</p><p>&nbsp;</p><p><u>Hyperkalaemia</u>:</p><p>Patients on quinapril alone may have increased serum potassium levels. Because of the risk of further potentiating increases in serum potassium it is advised that combination therapy with potassium-sparing diuretics or other drugs known to raise serum potassium levels, be initiated with caution and the patient&rsquo;s serum potassium levels be closely monitored (see Hypotension below and section 4.5). When administered concomitantly, quinapril may reduce the hypokalaemia induced by thiazide diuretics.</p><p>&nbsp;</p><p><u>Hyponatraemia and Syndrome of Inappropriate Anti-Diuretic Hormone (SIADH):</u></p><p>Syndrome of Inappropriate Anti-Diuretic Hormone (SIADH) and subsequent hyponatraemia has been observed in some patients treated with other ACE inhibitors. It is recommended that serum sodium levels be monitored regularly in the elderly and in other patients at risk of hyponatraemia.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Diabetic Patients </u></p><p>In diabetic patients ACE inhibitors may enhance insulin sensitivity and have been associated with hypoglycaemia in patients treated with oral antidiabetic agents or insulin. Glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (see section 4.5).</p><p>&nbsp;</p><p><u>Anaphylactoid Reactions</u>:</p><p>Patients receiving ACE inhibitors during desensitising treatment with hymenoptera venom have experienced life threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each desensitisation, but they have reappeared upon inadvertent re-challenge.</p><p>&nbsp;</p><p><u>Impaired Renal Function:</u></p><p>In patients with renal insufficiency, monitoring of renal function during therapy should be performed as deemed appropriate, although in the majority renal function will not alter or may improve.</p><p>&nbsp;</p><p>As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors including quinapril, may be associated with oliguria and/or progressive azotaemia and rarely acute renal failure and/or death.</p><p>&nbsp;</p><p>The half-life of quinaprilat is prolonged as creatinine clearance falls. Patients with a creatinine clearance of &lt;60 mL/min require a lower initial dosage of quinapril (see section 4.2 )These patients&#39; dosage should be titrated upwards based upon therapeutic response, and renal function should be closely monitored although initial studies do not indicate that quinapril produces further deterioration in renal function.</p><p>&nbsp;</p><p>In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine have been observed in some patients following ACE inhibitor therapy. These increases were almost always reversible upon discontinuation of the ACE inhibitor and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy.</p><p>&nbsp;</p><p>Some patients with hypertension or heart failure with no apparent pre-existing renal disease have developed increases (&gt;1.25 times the upper limit of normal) in blood urea nitrogen and serum creatinine, usually minor and transient, especially when quinapril has been given concomitantly with a diuretic. Increases in blood urea nitrogen and serum creatinine have been observed in 2% and 2%, respectively of hypertensive patients on quinapril monotherapy and in 4% and 3%, respectively of hypertensive patients on quinapril/HCTZ. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or quinapril may be required.</p><p>&nbsp;</p><p><u>Dual Blockade of the </u><em>Renin-Angiotensin-Aldosterone System </em><u>(RAAS):</u></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>There is insufficient experience in patients with severe renal impairment (creatinine clearance &lt;10 mL/min). Treatment is therefore not recommended in these patients.</p><p>&nbsp;</p><p><u>Angioedema:</u></p><p>Angioedema has been reported in patients treated with ACE inhibitors. If laryngeal stridor or angioedema of the face, tongue, or glottis occur, treatment should be discontinued immediately, the patient treated appropriately in accordance with accepted medical care, and carefully observed until the swelling disappears. In instances where swelling is confined to the face and lips, the condition generally resolves without treatment; antihistamines may be useful in relieving symptoms. Angioedema associated with laryngeal involvement may be fatal. Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, appropriate therapy e.g., subcutaneous adrenaline solution 1:1000 (0.3 to 0.5 mL) should be promptly administered.</p><p>&nbsp;</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of</p><p>angioedema while receiving an ACE inhibitor (see section 4.3).<u> </u></p><p><u>&nbsp;</u></p><p>The combination of quinapril with sacubitril/valsartan is contraindicated due to the increased risk of angioedema (see section 4.3). Sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of quinapril therapy. If treatment with sacubitril/valsartan is stopped, quinapril therapy must not be initiated until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.5). Concomitant use of other NEP inhibitors (e.g. racecadotril) and ACE inhibitors may also increase the risk of angioedema (see section 4.5). Hence, a careful benefit-risk assessment is needed before initiating treatment with NEP inhibitors (e.g. racecadotril) in patients on quinapril.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p>Patients taking concomitant mTOR inhibitor (e.g. temsirolimus) or concomitant DPP-IV inhibitor (e.g. vildagliptin) therapy may be at increased risk for angioedema. Caution should be used when starting an mTOR inhibitor or a DPP-IV inhibitor in a patient already taking an ACE inhibitor.</p><p>&nbsp;</p><p><u>Ethnic Differences: </u></p><p>Black patients receiving ACE inhibitor therapy have been reported to have a higher incidence of angioedema compared to non-black patients. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-black patients.</p><p><u>&nbsp;</u></p><p><u>Intestinal Angioedema</u>:</p><p>Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.</p><p>&nbsp;</p><p><u>Hypotension</u>:</p><p>Symptomatic hypotension was rarely seen in uncomplicated hypertensive patients treated with Acuitel but it is a possible consequence of ACE inhibitor therapy particularly in salt/volume depleted patients such as those previously treated with diuretics, who have a dietary salt reduction, who are on dialysis, have diarrhoea or vomiting or have severe renin-dependent hypertension. If symptomatic hypotension occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses; however, lower doses of quinapril or any concomitant diuretic therapy should be considered if this event occurs.</p><p>&nbsp;</p><p>In patients with congestive heart failure, who are at risk of excessive hypotension, quinapril therapy should be started at the recommended dose under close medical supervision; these patients should be followed closely for the first 2 weeks of treatment and whenever the dosage of quinapril is increased.</p><p>&nbsp;</p><p>Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>&nbsp;</p><p><u>Neutropenia/Agranulocytosis</u>:</p><p>ACE inhibitors have been rarely associated with agranulocytosis and bone marrow depression in patients with uncomplicated hypertension but more frequently in patients with renal impairment, especially if they also have collagen vascular disease. As with other ACE inhibitors, monitoring of white blood cell counts in patients with collagen vascular disease and/or renal diseases should be considered.</p><p>&nbsp;</p><p><u>Pregnancy</u>:</p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>&nbsp;</u></p><p><u>Lactose:</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or</p><p>glucose/galactose malabsorption should not use this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tetracycline and Other Drugs That Interact with Magnesium: </u></p><p>Because of the presence of magnesium carbonate in the formulation, Acuitel has been shown in healthy volunteers to reduce the absorption of tetracycline in concomitant administration by 28-37%. This interaction should be considered if co-prescribing quinapril and tetracycline. It is recommended that concomitant administration with tetracycline be avoided.</p><p>&nbsp;</p><p><u>Concomitant Diuretic Therapy: </u></p><p>Patients treated with diuretics, especially those on recently instituted diuretic therapy, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Acuitel. This hypotensive effect may be effectively minimised by either discontinuing the diuretic a few days prior to initiation of therapy, or increasing the salt intake prior to the initial dose of Acuitel. If discontinuation of the diuretic is not possible, the starting dose of Acuitel should be reduced and medical supervision should be provided for up to two hours following administration of the initial dose (see section 4.4 and 4.2 ).</p><p>&nbsp;</p><p><u>Agents Increasing Serum Potassium: </u></p><p>Quinapril is an ACE inhibitor capable of lowering aldosterone levels, which in turn can result in elevation in serum potassium. Concomitant treatments with potassium sparing diuretics, potassium supplements, potassium salts or other drugs known to raise serum potassium levels should be used with caution and with appropriate monitoring of serum potassium. As with other ACE inhibitors, patients on quinapril alone may have increased serum potassium levels. When administered concomitantly, quinapril may reduce the hypokalaemia induced by thiazide diuretics. In patients who are elderly or have compromised renal function, co-administration of an ACE inhibitor with sulfamethoxazole/trimethoprim has been associated with severe hyperkalaemia, which is thought to be due to trimethoprim. Quinapril and trimethoprim-containing products should therefore be co-administered with caution and with appropriate monitoring of serum potassium.</p><p>&nbsp;</p><p><u>Surgery/Anaesthesia:</u></p><p>Although no data are available to indicate there is an interaction between Acuitel and anaesthetic agents that produces hypotension, caution should be exercised when patients undergo major surgery or anaesthesia since ACE inhibitors have been shown to block angiotensin II formation secondary to compensatory renin release. This may lead to hypotension which can be corrected by volume expansion (see section 4.4).</p><p>&nbsp;</p><p><u>Lithium<strong>:</strong></u><strong> </strong></p><p>Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy due to the sodium-losing effect of these agents. These drugs should be co-administered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of lithium toxicity.</p><p>&nbsp;</p><p><u>Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 inhibitors):</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of </u>non-steroidal anti-inflammatory drugs (<u>NSAIDs), including selective COX-2 inhibitors, with ACE inhibitors, including quinapril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving quinapril and NSAID therapy.</u></p><p><u>The antihypertensive effect of ACE inhibitors, including quinapril may be attenuated by NSAIDs.<sup> </sup></u></p><p>&nbsp;</p><p><u>Other drugs known to cause Angioedema:</u>Patients taking concomitant mTOR inhibitor (e.g. temsirolimus) or concomitant DPP-IV inhibitor (e.g. vildagliptin) therapy may be at increased risk for angioedema. Caution should be used when starting an mTOR inhibitor or a DPP-IV inhibitor in a patient already taking an ACE inhibitor.</p><p>&nbsp;</p><p><u>NEP Inhibitors:</u></p><p>The concomitant use of quinapril with sacubitril/valsartan is contraindicated, as the concomitant inhibition of neprilysin (NEP) and ACE may increase the risk of angioedema. Sacubitril/valsartan must not be started until 36 hours after taking the last dose of quinapril therapy. Quinapril therapy must not be started until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.4). Concomitant use of other NEP inhibitors (e.g. racecadotril) and quinapril may also increase the risk of angioedema (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Gold:</u></p><p>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (e.g. sodium aurothiomalate) and concomitant ACE inhibitor therapy.</p><p>&nbsp;</p><p><u>Allopurinol, Cytostatic and Immunosuppressive Agents, Systemic Corticosteroids or Procainamide:</u></p><p>Concomitant administration with ACE inhibitors may lead to an increased risk for leukopenia..</p><p>&nbsp;</p><p><u>Alcohol, Barbiturates or Narcotics:</u></p><p>Potentiation of orthostatic hypotension may occur.</p><p>&nbsp;</p><p><u>Other Hypertensive Drugs:</u></p><p>There may be an additive effect or potentiation.</p><p><u>&nbsp;</u></p><p><u>Other Agents:</u></p><p>Co-administration of multiple 10 mg doses of atorvastatin with 80 mg quinapril resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.</p><p>&nbsp;</p><p><u>Antacids:</u></p><p>Antacids may decrease the bioavailability of quinapril.</p><p>&nbsp;</p><p><u>Antidiabetic Agents (Oral Hypoglycaemic Agents and Insulin)</u>:</p><p>In diabetic patients ACE inhibitors may enhance insulin sensitivity and have been associated with hypoglycaemia in patients treated with oral antidiabetic agents and insulin. Glycaemic control should be closely monitored particularly during the first month of treatment with an ACE inhibitor (see section 4.4).</p><p>&nbsp;</p><p><u>Dual Blockade of the Renin-Angiotensin-Aldosterone-System (RAAS):</u></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p><u>Aliskiren:</u></p><p>Do not co-administer aliskiren with quinapril in patients with diabetes or in patients with renal impairment (GFR &lt;60 mL/min/1.73m<sup>2</sup>).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy:</em></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contraindicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation and/or death in the newborn) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3.). Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.&nbsp; Limb contractures, craniofacial deformities, hypoplastic lung development and intrauterine growth retardation have been reported in association with oligohydramnios.</p><p>&nbsp;</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension, oliguria and hyperkalaemia. (see sections 4.3 and 4.4). If oliguria occurs, attention should be directed towards support of blood pressure and renal perfusion.</p><p>&nbsp;</p><p><u>Breast-feeding</u><em> </em>:</p><p>Limited pharmacokinetic data demonstrate very low concentrations in breast milk (see section 5.2). Although these concentrations seem to be clinically irrelevant, the use of Acuitel<strong> </strong>in breastfeeding is not recommended for preterm infants and for the first few weeks after delivery, because of the hypothetical risk of cardiovascular and renal effects and because there is not enough clinical experience.</p><p>&nbsp;</p><p>In the case of an older infant, the use of Acuitel<strong> </strong>in a breast-feeding mother may be considered if this treatment is necessary for the mother and the child is observed for any adverse effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no studies on the effect of this medicine on the ability to drive. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects have been observed and reported during treatment with quinapril with the following frequencies: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&le;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>The most frequently adverse reactions found in controlled clinical trials were headache (7.2%), dizziness (5.5%), cough (3.9%), fatigue (3.5%), rhinitis (3.2%), nausea and/or vomiting (2.8%) and myalgia (2.2%).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Undesirable effects</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Pharyngitis, rhinitis</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Bronchitis, upper respiratory tract infection, urinary tract infection, sinusitis</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Agranulocytosis, haemolytic anaemia, neutropenia, thrombocytopenia</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Anaphylactoid reaction</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Hyperkalaemia</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Hyponatraemia (see section 4.4)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Confusional state, depression, nervousness</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Dizziness, headache, paraesthesia</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Transient ischaemic attack, somnolence&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Balance disorder, syncope</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Cerebrovascular accident/cerebral haemorrhage</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Amblyopia</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td colspan="2" style="vertical-align:top"><p>Vision blurred</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Vertigo, tinnitus</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Myocardial infarction, angina pectoris, tachycardia, palpitations</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Vasodilatation</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Orthostatic hypotension</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="4" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Dyspnoea, cough</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Dry throat</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Eosinophilic pneumonia</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Bronchospasm.</p><p>In individual cases, upper airways obstruction by angioedema (that may be fatal)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Vomiting, diarrhoea, dyspepsia, abdominal pain, nausea</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Flatulence, dry mouth</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Glossitis, constipation, dysgeusia</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td colspan="2" style="vertical-align:top"><p>Ileus, small bowel angioedema</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Pancreatitis*</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Hepato-biliary disorders</strong></p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Hepatitis, jaundice cholestatic</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Angioedema, rash, pruritus, hyperhidrosis</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Erythema multiforme, pemphigus, urticaria</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td colspan="2" style="vertical-align:top"><p>Dermatitis psoriasis form</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Stevens Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, alopecia, photosensitivity reaction.</p><p>Skin disorders may be associated with pyrexia, muscle and joint pain (myalgia, arthralgia, arthritis), vascular inflammation (vasculitis), inflammation of serous tissues and certain changes in laboratory values (eosinophilia, leukocytosis and/or antinuclear antibody increased, red blood sedimentation rate increased).</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Back pain, myalgia</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Renal impairment, proteinuria</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Fatigue, asthenia, chest pain</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Generalised oedema, pyrexia, oedema peripheral</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Blood creatinine increased, blood urea increased**</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known</p></td><td colspan="2" style="vertical-align:top"><p>Haemoglobin decreased, haematocrit decreased, decreases in haematocrit and WCXC, hepatic enzyme increased, blood bilirubin increased. In patients with a congenital G-6-PDH deficiency, individual cases of haemolytic anaemia have been reported.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>* Pancreatitis has been reported rarely in patients treated with ACE inhibitors; in some cases this has proved fatal.</p><p>** Such increases are more likely to occur in patients receiving concomitant diuretic therapy than those on monotherapy with quinapril. These observed increases will often reverse on continued therapy.</p><p>&nbsp;</p><p>Vasculitis and gynecomastia have been reported with other ACE inhibitors and it cannot be excluded that these unwanted effects are class specific.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Syndrome of Inappropriate Anti-diuretic Hormone (SIADH) and subsequent hyponatraemia has been observed in some patients treated with other ACE inhibitors (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions:</u></strong></p><p><br />Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local country requirements</u>.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:438px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>Call center : 19999</p><p>Fax: +966 11 205 7662</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website :https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The oral LD50 of quinapril in mice and rats ranges from 1440 to 4280 mg/kg.</p><p>&nbsp;</p><p>No data are available with respect to overdosage in humans. The most likely clinical manifestation would be symptoms attributable to severe hypotension, which should normally be treated by intravenous volume expansion.</p><p>&nbsp;</p><p>Haemodialysis and peritoneal dialysis have little effect on the elimination of quinapril and quinaprilat.</p><p>&nbsp;</p><p>Treatment is symptomatic and supportive consistent with established medical care.</p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin-converting enzyme (ACE) inhibitor, plain</p><p>ATC code: CO9A AO6</p><p><strong>&nbsp;</strong></p><p><u>&nbsp;</u></p><p>Quinapril is rapidly de-esterified to quinaprilat (quinapril diacid, the principal metabolite) which is a potent ACE inhibitor.</p><p>&nbsp;</p><p>ACE is a peptidyl dipeptidase that catalyses the conversion of angiotensin I to the vasoconstrictor angiotensin II which is involved in vascular control and function through many different mechanisms, including stimulation of aldosterone secretion by the adrenal cortex. The mode of action of quinapril in humans and animals is to inhibit circulating and tissue ACE activity, thereby decreasing vasopressor activity and aldosterone secretion.</p><p>&nbsp;</p><p>In animal studies, the antihypertensive effect of quinapril outlasts its inhibitory effect on circulating ACE, whereas, tissue ACE inhibition more closely correlates with the duration of antihypertensive effects. Administration of 10 mg to 40 mg of quinapril to patients with mild to severe hypertension results in a reduction of both sitting and standing blood pressure with minimal effect on heart rate. Antihypertensive activity commences within 1 hour with peak effects usually achieved by 2 to 4 hours after dosing. Achievement of maximum blood pressure lowering effects may require 2 weeks of therapy in some patients. At the recommended doses, antihypertensive effects are maintained in most patients throughout the 24 hour dosing interval and continued during long term therapy.</p><p>&nbsp;</p><p>In a randomised clinical trial using target doses of 2.5 mg, 5 mg, 10 mg and 20 mg of quinapril, in 112 children and adolescents with hypertension or high normal blood pressure over 8 weeks (2 weeks double blind and 6 weeks extension) failed to reach its primary objective of reduction of diastolic blood pressure after 2 weeks. For systolic blood pressure (secondary objective of efficacy) at Week 2 only there was a statistically significant linear dose response across treatments with a significant difference between the quinapril 20 mg QD and placebo treatment groups.</p><p>&nbsp;</p><p>Long term effects of quinapril on growth, puberty and general development have not been studied.</p><p>&nbsp;</p><p>Two large randomised, controlled trials (ONTARGET (On-going Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>&nbsp;</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>&nbsp;</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Peak plasma Acuitel concentrations are observed within 1 hour of oral administration. The extent of absorption is approximately 60%, and is not influenced by food. Following absorption, Acuitel is de-esterified to its major active metabolite, quinaprilat, and to minor inactive metabolites. Acuitel has an apparent half-life of approximately 1 hour. Peak plasma quinaprilat concentrations are observed approximately 2 hours following an oral dose of quinapril. Quinaprilat is eliminated primarily by renal excretion and has an effective accumulation half-life of 3 hours. In patients with renal insufficiency and creatinine clearance of <u>&lt;</u>40 mL/min, peak and trough quinaprilat concentrations increase, time to peak concentration increases, apparent half-life increases, and time to steady state may be delayed. The elimination of quinaprilat is also reduced in elderly patients (&gt;65 years) and correlates well with the impaired renal function which frequently occurs in the elderly. Quinaprilat concentrations are reduced in patients with alcoholic cirrhosis due to impaired de-esterification of Acuitel. Studies in rats indicate that Acuitel and its metabolites do not cross the blood-brain barrier.</p><p>&nbsp;</p><p><em>Lactation:</em></p><p>After a single oral dose of 20 mg of quinapril in six breast-feeding women, the M/P (milk to plasma ratio) for quinapril was 0.12. Quinapril was not detected in milk after 4 hours after the dose. Quinalaprilat milk levels were undetectable (&lt;5 &micro;g/L) at all time points. It is estimated that a breastfed infant would receive about 1.6% of the maternal weight-adjusted dosage of quinapril.</p><p>&nbsp;</p><p>The pharmacokinetics of quinapril has been studied in a single dose study (0.2 mg/kg) in 24 children aged 2.5 months to 6.8 years and a multiple dose study (0.016-0.468 mg/kg) in 38 children aged 5-16 years old, weighing 66-98 kg on average.</p><p>&nbsp;</p><p>As in adults, quinapril was rapidly converted to quinaprilat. Quinaprilat concentrations generally peaked 1 to 2 hours post dose and declined with a mean half-life of 2.3 hours. In infants and young children the exposure following a single 0.2 mg/kg dose is comparable to that observed in adults after a single 10 mg dose. In a multiple dose study in school age and adolescents, the AUC and Cmax values of quinaprilat were observed to increase linearly with increasing dose of quinapril on a mg/kg basis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The results of the preclinical tests do not add anything of further significance to the prescriber.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Magnesium carbonate</p><p>Hydrous lactose</p><p>Gelatin</p><p>Crospovidone</p><p>Magnesium stearate</p><p>Candelilla wax</p><p>Colourings (Opadry White OY-S-7331) &nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25 &nbsp;<sup>o</sup>C</p><p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acuitel is packaged in Al-PA/Al/PVC (aluminium-polyamide/aluminium/polyvinyl chloride) blisters and supplied in &nbsp;a pack of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special instructions needed</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Pharma PFE GmbH
Linkster, Berlin
Germany

Manufactured, Packaged  and Released By :

Pfizer Manufacturing Deutschland GmbH
Freiburg, Germany 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>